PNAS

Supporting Information for
WDFY4 deficiency in NOD mice ameliorates autoimmune diabetes and insulitis

Stephen T. Ferris[1,2*], Tiantian Liu[1], Jing Chen[1], Ray A. Ohara[1], Feiya Ou[1], Renee Wu[1], Sunkyung Kim[1], Theresa L. Murphy[1], and Kenneth M. Murphy[1*]

[1]Department of Pathology and Immunology, Washington University in St. Louis, School of Medicine, St. Louis, MO, 63110, USA;
[2] Current address: Department of Molecular Microbiology and Immunology, School of Medicine, Saint Louis University, St. Louis MO, 63104, USA

*Lead Contact to whom correspondence should be addressed.
Phone: 314-263-2004, email: kmurphy@wustl.edu
Phone: 314-977-8788, email: stephen.ferris@health.slu.edu

This PDF file includes:

Figures S1 to S2

Supplementary Figure 1



Fig. S1. Generation of NOD.*Wdfy4*$^{-/-}$ mice.

(a) Targeting design using CRISPR Cas9 to delete *Wdfy4* exon 4.

(b) Sequence showing sgRNAs, screening primers, and exons and introns for *Wdfy4* targeting design.

(c) Gel of genotyping for NOD.*Wdfy4*$^{-/-}$, NOD.*Wdfy4*$^{+/-}$, NOD.*Wdfy4*$^{+/+}$ mice

Supplementary Figure 2



Fig. S2. Gating strategy for dispersed islets.

Representative flow plots from 12 week NOD.*Wdfy4*$^{-/-}$ (KO, top) and female NOD.*Wdfy4*$^{+/-}$ (Het, bottom).